[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

November 2018 - April 2015

Decade

Year

Issue

September 2015, Vol 1, No. 6, Pages 713-850

Original Investigation

Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):737-745. doi:10.1001/jamaoncol.2015.1796

This cohort study found that among women with primary invasive epithelial ovarian cancer, dose reduction for paclitaxel and carboplatin was associated with poorer survival, and body mass index was the strongest predictor of dose reduction.

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

Abstract Full Text
open access
JAMA Oncol. 2015;1(6):746-754. doi:10.1001/jamaoncol.2015.2010

In this pilot study of patients with newly diagnosed or smoldering multiple myeloma, carfilzomib-lenalidomide-dexamethasone therapy was tolerable and demonstrated high rates of minimal residual disease negativity.

Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Abstract Full Text
free access has expired quiz
JAMA Oncol. 2015;1(6):756-765. doi:10.1001/jamaoncol.2015.2189

This systematic review and meta-analysis determined that transcatheter arterial chemoembolization (TACE) plus radiotherapy was more therapeutically beneficial than TACE alone for treating hepatocellular carcinoma.

Effects of a High vs Moderate Volume of Aerobic Exercise on Adiposity Outcomes in Postmenopausal Women: A Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2015;1(6):766-776. doi:10.1001/jamaoncol.2015.2239

In a randomized clinical trial of previously inactive postmenopausal women, a 1-year prescription of moderate to vigorous exercise for 300 min/wk was superior to 150 min/wk for reducing total fat and several other adiposity measures, especially in obese women, but not intra-abdominal fat.

Chemotherapy Use, Performance Status, and Quality of Life at the End of Life

Abstract Full Text
open access
JAMA Oncol. 2015;1(6):778-784. doi:10.1001/jamaoncol.2015.2378

This multi-institutional, longitudinal cohort study finds that palliative chemotherapy did not improve quality of life near death for cancer patients with moderate or poor performance status and worsened quality of life near death for cancer patients with good performance status.

Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):787-795. doi:10.1001/jamaoncol.2015.1790

This systematic review finds that survival gains in first-line treatments of metastatic colorectal cancer over the last 22 years have been modest but steady.

Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):797-805. doi:10.1001/jamaoncol.2015.2407

This retrospective observational medical chart review determined that, overall, physicians tended to underestimate the risk of recurrence for many patients with gastrointestinal stromal tumors.

Cost-effectiveness of Lung Cancer Screening in Canada

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):807-813. doi:10.1001/jamaoncol.2015.2472

This study assesses the cost-effectiveness of low-dose computed tomographic scan screening for lung cancer within the Canadian health care system using the Cancer Risk Management Model.

Brief Report

Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):814-819. doi:10.1001/jamaoncol.2015.1883

This small case series shows that maternal plasma cell-free DNA sequencing for noninvasive prenatal testing also enables accurate presymptomatic detection of maternal tumors and treatment during pregnancy.

Research Letter

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):836-838. doi:10.1001/jamaoncol.2015.0736

This case report describes the first use of vemurafenib in an infant with BRAF V600E–mutated Langerhans cell histiocytosis, showing improvement in the patient’s general health and eventual complete remission.

Successful Treatment of Non–Small Cell Lung Cancer With Erlotinib Throughout Pregnancy

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):838-840. doi:10.1001/jamaoncol.2015.1300

This Research Letter describes a patient, 10-weeks pregnant with dichorionic-diamniotic twins, diagnosed as having a stage IV exon 19 deletion adenocarcinoma. She was treated with erlotinib; both lung lesions became cystic, and all brain lesions were smaller.

Review

Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):820-828. doi:10.1001/jamaoncol.2015.0617

This review categorizes acute myeloid leukemia into biologically defined groups and describes the evolving treatment approaches for each.

JAMA Oncology Clinical Challenge

Lesion on the Plantar Foot

Abstract Full Text
JAMA Oncol. 2015;1(6):833-834. doi:10.1001/jamaoncol.2015.2107

A man with transformed marginal zone lymphoma presented with intensely painful lesions on his left foot and pruritic rash on his left thigh that had started several days before the appearance of his plantar foot lesions. What is your diagnosis?

Viewpoint

Appropriate Use of Psychology in Patient-Physician Communication: Influencing Wisely

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):725-726. doi:10.1001/jamaoncol.2015.0980

This Viewpoint discusses 3 principles of behavioral psychology that provide insight into how patients’ treatment preferences are influenced in serious illnesses.

Benefits of Adjuvant Chemotherapy for Bladder Cancer

Abstract Full Text
JAMA Oncol. 2015;1(6):727-728. doi:10.1001/jamaoncol.2015.1210

This Viewpoint reviews the convergence of evidence in support of adjuvant chemotherapy for bladder cancer and proposes that despite the lack of level 1 evidence it is time for perioperative chemotherapy for bladder cancer (neoadjuvant or adjuvant) to become standard of care.

Having “Skin in the Game” and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs

Abstract Full Text
JAMA Oncol. 2015;1(6):729-730. doi:10.1001/jamaoncol.2015.1024

This Viewpoint discusses the differential prices of drugs in the United States vs Canada and England and cross-border drug importation. Competitive market forces would function better, lower cancer drug prices, and would benefit all parties.

From The JAMA Network

Why Do Airline Pilots and Flight Crews Have an Increased Incidence of Melanoma?

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):829-830. doi:10.1001/jamaoncol.2015.0933

Prostate Cancer Diagnosis Using MR/Ultrasound–Fusion Guided Biopsy: Ending the “Needle in a Haystack” Conundrum?

Abstract Full Text
JAMA Oncol. 2015;1(6):831-832. doi:10.1001/jamaoncol.2015.1063

This commentary argues that the greater effectiveness of targeted magnetic resonance/ultrasound fusion prostate biopsy will eventually result in its replacing the simple ultrasound procedure, but owing to its greater complexity and level of difficulty, the change will take some time.

Editorial

Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet?

Abstract Full Text
JAMA Oncol. 2015;1(6):732-733. doi:10.1001/jamaoncol.2015.1926
Invited Commentary

Multiple Myeloma—Better Drugs Ask for More Stringent Evaluations

Abstract Full Text
JAMA Oncol. 2015;1(6):754-755. doi:10.1001/jamaoncol.2015.2009

Exercise and Cancer Risk—How Much Is Enough?

Abstract Full Text
JAMA Oncol. 2015;1(6):776-777. doi:10.1001/jamaoncol.2015.2267

Chemotherapy Near the End of Life: First—and Third and Fourth (Line)—Do No Harm

Abstract Full Text
JAMA Oncol. 2015;1(6):785-786. doi:10.1001/jamaoncol.2015.2379

Improved Outcomes in Metastatic Colon Cancer: Giving Credit Where Credit Is Due

Abstract Full Text
JAMA Oncol. 2015;1(6):795-796. doi:10.1001/jamaoncol.2015.1789

Physician Estimations of the Risk of Gastrointestinal Stromal Tumor Recurrence—Not Accurate Enough?More Education May Be Needed

Abstract Full Text
JAMA Oncol. 2015;1(6):805-806. doi:10.1001/jamaoncol.2015.2404
Editor's Note

Dual-Modality Liver-Directed Therapy for Primary Liver Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):765. doi:10.1001/jamaoncol.2015.2197
JAMA Oncology Patient Page

The Evolution of a Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):850. doi:10.1001/jamaoncol.2015.2199
Cancer Care Chronicles

Terminal Life

Abstract Full Text
JAMA Oncol. 2015;1(6):731. doi:10.1001/jamaoncol.2015.1533
Comment & Response

Let Them Eat Fish

Abstract Full Text
JAMA Oncol. 2015;1(6):840. doi:10.1001/jamaoncol.2015.2053

Let Them Eat Fish

Abstract Full Text
JAMA Oncol. 2015;1(6):840-841. doi:10.1001/jamaoncol.2015.2059

Pricing and Value of Cancer Drugs

Abstract Full Text
JAMA Oncol. 2015;1(6):841-842. doi:10.1001/jamaoncol.2015.1962

Let Them Eat Fish—Reply

Abstract Full Text
JAMA Oncol. 2015;1(6):841. doi:10.1001/jamaoncol.2015.2056

Pricing and Value of Cancer Drugs—Reply

Abstract Full Text
JAMA Oncol. 2015;1(6):842-843. doi:10.1001/jamaoncol.2015.1959
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):719. doi:10.1001/jamaoncol.2014.249
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2015;1(6):713. doi:10.1001/jamaoncol.2015.0727
×